Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review)
- Authors:
- Biaoxue Rong
- Shuanying Yang
-
Affiliations: Department of Oncology, First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, P.R. China, Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China - Published online on: November 29, 2017 https://doi.org/10.3892/ijo.2017.4214
- Pages: 321-336
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Biaoxue R, Xiguang C, Hua L and Shuanying Y: Stathmin-dependent molecular targeting therapy for malignant tumor: The latest 5 years' discoveries and developments. J Transl Med. 14:2792016. View Article : Google Scholar | |
|
Biao-xue R, Xi-guang C, Shuan-ying Y, Wei L and Zong-juan M: EphA2-dependent molecular targeting therapy for malignant tumors. Curr Cancer Drug Targets. 11:1082–1097. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Biaoxue R, Hua L, Wenlong G and Shuanying Y: Overexpression of stathmin promotes metastasis and growth of malignant solid tumors: A systemic review and meta-analysis. Oncotarget. 7:78994–79007. 2016.PubMed/NCBI | |
|
Tatokoro M, Koga F, Yoshida S and Kihara K: Heat shock protein 90 targeting therapy: State of the art and future perspective. EXCLI J. 14:48–58. 2015.PubMed/NCBI | |
|
Chehab M, Caza T, Skotnicki K, Landas S, Bratslavsky G, Mollapour M and Bourboulia D: Targeting Hsp90 in urothelial carcinoma. Oncotarget. 6:8454–8473. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hall JA, Forsberg LK and Blagg BS: Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Med Chem. 6:1587–1605. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Prodromou C: Mechanisms of Hsp90 regulation. Biochem J. 473:2439–2452. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Khurana N and Bhattacharyya S: Hsp90, the concertmaster: Tuning transcription. Front Oncol. 5:1002015. View Article : Google Scholar : PubMed/NCBI | |
|
Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, Dionigi G and Roukos DH: The role of heat shock proteins in cancer. Cancer Lett. 360:114–118. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W and Min Z: Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res. 31:702012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SH, Ji JH, Park KT, Lee JH, Kang KW, Park JH, Hwang SW, Lee EH, Cho YJ, Jeong YY, et al: High-level expression of Hsp90β is associated with poor survival in resectable non-small-cell lung cancer patients. Histopathology. 67:509–519. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Miyata Y and Yahara I: The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. J Biol Chem. 267:7042–7047. 1992.PubMed/NCBI | |
|
Rong B, Zhao C, Liu H, Ming Z, Cai X, Gao W and Yang S: Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer. Am J Cancer Res. 4:874–885. 2014.PubMed/NCBI | |
|
Pillai RN and Ramalingam SS: Heat shock protein 90 inhibitors in non-small-cell lung cancer. Curr Opin Oncol. 26:159–164. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pennisi R, Ascenzi P and Di Masi A: Hsp90: A new player in DNA repair? Biomolecules. 5:2589–2618. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maloney A and Workman P: HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther. 2:3–24. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Li J and Buchner J: Structure, function and regulation of the hsp90 machinery. Biomed J. 36:106–117. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Verma S, Goyal S, Jamal S, Singh A and Grover A: Hsp90: Friends, clients and natural foes. Biochimie. 127:227–240. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Fok JH and Davies FE: Heat shock proteins in multiple myeloma. Oncotarget. 5:1132–1148. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
García R, Merino D, Gómez JM, Nistal JF, Hurlé MA, Cortajarena AL and Villar AV: Extracellular heat shock protein 90 binding to TGFβ receptor I participates in TGFβ-mediated collagen production in myocardial fibroblasts. Cell Signal. 28:1563–1579. 2016. View Article : Google Scholar | |
|
Prodromou C, Siligardi G, O'Brien R, Woolfson DN, Regan L, Panaretou B, Ladbury JE, Piper PW and Pearl LH: Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J. 18:754–762. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Richter K, Muschler P, Hainzl O, Reinstein J and Buchner J: Sti1 is a non-competitive inhibitor of the Hsp90 ATPase Binding prevents the N-terminal dimerization reaction during the ATPase cycle. J Biol Chem. 278:10328–10333. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Obermann WM, Sondermann H, Russo AA, Pavletich NP and Hartl FU: In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol. 143:901–910. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Silverstein AM, Galigniana MD, Chen MS, Owens-Grillo JK, Chinkers M and Pratt WB: Protein phosphatase 5 is a major component of glucocorticoid receptor hsp90 complexes with properties of an FK506-binding immunophilin. J Biol Chem. 272:16224–16230. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Wandinger SK, Suhre MH, Wegele H and Buchner J: The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J. 25:367–376. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Pirkl F and Buchner J: Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40. J Mol Biol. 308:795–806. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Srikakulam R, Liu L and Winkelmann DA: Unc45b forms a cytosolic complex with Hsp90 and targets the unfolded myosin motor domain. PLoS One. 3:e21372008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao R, Kakihara Y, Gribun A, Huen J, Yang G, Khanna M, Costanzo M, Brost RL, Boone C, Hughes TR, et al: Molecular chaperone Hsp90 stabilizes Pih1/Nop17 to maintain R2TP complex activity that regulates snoRNA accumulation. J Cell Biol. 180:563–578. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hessling M, Richter K and Buchner J: Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat Struct Mol Biol. 16:287–293. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Soroka J and Buchner J: The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones. Biochim Biophys Acta. 1823:624–635. 2012. View Article : Google Scholar | |
|
Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y and Neckers L: Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem. 276:3702–3708. 2001. View Article : Google Scholar | |
|
Schwartzberg PL: The many faces of Src: Multiple functions of a prototypical tyrosine kinase. Oncogene. 17:1463–1468. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Perdew GH, Wiegand H, Vanden Heuvel JP, Mitchell C and Singh SSA: A 50 kilodalton protein associated with raf and pp60(v-src) protein kinases is a mammalian homolog of the cell cycle control protein cdc37. Biochemistry. 36:3600–3607. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stancato LF, Chow YH, Owens-Grillo JK, Yem AW, Deibel MR Jr, Jove R and Pratt WB: The native v-Raf hsp90 p50 heterocomplex contains a novel immunophilin of the FK506 binding class. J Biol Chem. 269:22157–22161. 1994.PubMed/NCBI | |
|
Miyata Y and Yahara I: Interaction between casein kinase II and the 90-kDa stress protein, HSP90. Biochemistry. 34:8123–8129. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Holt SE, Aisner DL, Baur J, Tesmer VM, DY M, Ouellette M, Trager JB, Morin GB, Toft DO, Shay JW, et al: Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. 13:817–826. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
DeZwaan DC, Toogun OA, Echtenkamp FJ and Freeman BC: The Hsp82 molecular chaperone promotes a switch between unextendable and extendable telomere states. Nat Struct Mol Biol. 16:711–716. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sarkar S, Dutta D, Samanta SK, Bhattacharya K, Pal BC, Li J, Datta K and Mandal C and Mandal C: Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo. Int J Cancer. 132:695–706. 2013. View Article : Google Scholar | |
|
Song X, Wang X, Zhuo W, Shi H, Feng D, Sun Y, Liang Y, Fu Y, Zhou D and Luo Y: The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesis. J Biol Chem. 285:40039–40049. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Walerych D, Gutkowska M, Klejman MP, Wawrzynow B, Tracz Z, Wiech M, Zylicz M and Zylicz A: ATP binding to Hsp90 is sufficient for effective chaperoning of p53 protein. J Biol Chem. 285:32020–32028. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Park SJ, Borin BN, Martinez-Yamout MA and Dyson HJ: The client protein p53 adopts a molten globule-like state in the presence of Hsp90. Nat Struct Mol Biol. 18:537–541. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Zhai S, Li L, Li X, Zhou H, Liu A, Su G, Mu Q, Du Y and Yan B: Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models. Biochem Pharmacol. 86:351–360. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Yu Z, Wang Y, Wang X, Zhang L, Wang C, Yue Q, Wang X, Deng S, Huo X, et al: Quantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancer. Oncotarget. 7:76551–76564. 2016.PubMed/NCBI | |
|
Su JM, Hsu YY, Lin P and Chang H: Nuclear accumulation of heat-shock protein 90 is associated with poor survival and metastasis in patients with non-small cell lung cancer. Anticancer Res. 36:2197–2203. 2016.PubMed/NCBI | |
|
Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, Jassem E, Niklinski J, Muley T, van Zandwijk N, et al: Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One. 3:e00017222008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Wu Y, Wang L, Gao L, Wang Y, Liu X, Zhang K, Song J, Wang H, Bayer TA, et al: Protein signature for non-small cell lung cancer prognosis. Am J Cancer Res. 4:256–269. 2014.PubMed/NCBI | |
|
Gomez-Casal R, Epperly MW, Wang H, Proia DA, Greenberger JS and levina V: Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition. Oncotarget. 6:44306–44322. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu T, Wang X and Zhang L: The correlation between the up-regulation of Hsp90 and drug resistance to cisplatin in lung cancer cell line. Zhongguo Fei Ai Za Zhi. 14:472–477. 2011.In Chinese. PubMed/NCBI | |
|
Senju M, Sueoka N, Sato A, Iwanaga K, Sakao Y, Tomimitsu S, Tominaga M, Irie K, Hayashi S and Sueoka E: Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol. 132:150–158. 2006. View Article : Google Scholar | |
|
Wu Y, Huang B, Liu Q and Liu Y: Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients. Int J Clin Exp Pathol. 8:8252–8259. 2015. | |
|
Wang M, Feng L, Li P, Han N, Gao Y and Xiao T: Hsp90AB1 protein is overexpressed in non-small cell lung cancer tissues and associated with poor prognosis in lung adenocarcinoma patients. Zhongguo Fei Ai Za Zhi. 19:64–69. 2016.In Chinese. PubMed/NCBI | |
|
Shi Y, Liu X, Lou J, Han X, Zhang L, Wang Q, Li B, Dong M and Zhang Y: Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses. Clin Cancer Res. 20:6016–6022. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YQ, Shen AJ, Sun JY, Wang X, Liu HC, Zhang MM, Chen DQ, Xiong B, Shen JK, Geng MY, et al: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells. Acta Pharmacol Sin. 37:1587–1596. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gaponova AV, Nikonova AS, Deneka AY, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Ogawa LS, Cai KQ, Duncan KE, et al: A novel HSP90 inhibitor-drug conjugate to Sn38 is highly effective in small cell lung cancer. Clin Cancer Res. 22:5120–5129. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Niu B, Lin J and Feng T: Effects of 17-AAG on the proliferation and apoptosis of human lung cancer A549 and H446 cells. Zhonghua Jie He He Hu Xi Za Zhi. 38:267–272. 2015.In Chinese. PubMed/NCBI | |
|
Hirakawa H, Fujisawa H, Masaoka A, Noguchi M, Hirayama R, Takahashi M, Fujimori A and Okayasu R: The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells. Cancer Med. 4:426–436. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Zhai S, Li L, Li X, Jiang C, Zhang C and Yan B: P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model. J Pharmacol Sci. 126:66–76. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, et al: The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 30:2581–2586. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gallerne C, Prola A and Lemaire C: Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta. 1833:1356–1366. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Seo YH: Discovery of 2′,4′-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC). Arch Pharm Res. 38:1783–1788. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK and Choi CM: AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS One. 10:e01198322015. View Article : Google Scholar : PubMed/NCBI | |
|
Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, Asano H, Maki Y, Muraoka T, Tanaka N, et al: Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer. 76:26–31. 2012. View Article : Google Scholar | |
|
Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS and Jeong CH: Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification. Cancer Sci. 105:1245–1253. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC and Proia DA: The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target Oncol. 10:235–245. 2015. View Article : Google Scholar : | |
|
Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T and Yano S: Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 7:1078–1085. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, et al: The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer. 75:161–166. 2012. View Article : Google Scholar | |
|
Rice JW, Veal JM, Barabasz A, Foley B, Fadden P, Scott A, Huang K, Steed P and Hall S: Targeting of multiple signaling pathways by the Hsp90 inhibitor SnX-2112 in EGFR resistance models as a single agent or in combination with erlotinib. Oncol Res. 18:229–242. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Song X, Zhao Z, Qi X, Tang S, Wang Q, Zhu T, Gu Q, Liu M and Li J: Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90. Oncotarget. 6:5263–5274. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Park KS, Oh B, Lee MH, Nam KY, Jin HR, Yang H, Choi J, Kim SW and Lee DH: The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib. Cancer Lett. 372:75–81. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Takeuchi S, Fukuda K, Arai S, Nanjo S, Kita K, Yamada T, Hara E, Nishihara H, Uehara H and Yano S: Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer. Int J Cancer. 138:1281–1289. 2016. View Article : Google Scholar | |
|
Tung CL, Jian YJ, Syu JJ, Wang TJ, Chang PY, Chen CY, Jian YT and Lin YW: Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells. Exp Cell Res. 334:126–135. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tung CL, Chiu HC, Jian YJ, Jian YT, Chen CY, Syu JJ, Wo TY, Huang YJ, Tseng SC and Lin YW: Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells. Exp Cell Res. 322:345–354. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Weng SH, Tseng SC, Huang YC, Chen HJ and Lin YW: Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells. Biochem Pharmacol. 84:126–136. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, et al: Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 8:3296–3306. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH, Kim YS, Park HJ, Seo SY, Mills G, et al: A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila). 1:577–587. 2008. View Article : Google Scholar | |
|
Lee SC, Min HY, Choi H, Kim HS, Kim KC, Park SJ, Seong MA, Seo JH, Park HJ, Suh YG, et al: Synthesis and evaluation of a novel deguelin derivative, L80, which disrupts ATP binding to the C-terminal domain of heat shock protein 90. Mol Pharmacol. 88:245–255. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, et al: Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci. 104:1346–1352. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, et al: HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells. Regul Toxicol Pharmacol. 64:415–424. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y and Proia DA: Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther. 11:2633–2643. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ko JC, Chiu HC, Syu JJ, Chen CY, Jian YT, Huang YJ, Wo TY, Jian YJ, Chang PY, Wang TJ, et al: Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells. Biochem Biophys Res Commun. 456:506–512. 2015. View Article : Google Scholar | |
|
Lee KH, Jang AH and Yoo CG: 17-allylamino-17-demethoxygel-danamycin and the enhancement of PS-341-induced lung cancer cell death by blocking the NF-kappaB and PI3K/Akt pathways. Am J Respir Cell Mol Biol. 53:412–421. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Qu Z, Dong H, Xu X, Feng W and Yi X: Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway. Diagn Pathol. 8:702013. View Article : Google Scholar : PubMed/NCBI | |
|
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, et al: Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 3:430–443. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, et al: The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 12:890–900. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Sun W, Hao X, Li T, Su L and Liu X: Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells. Cancer Cell Int. 12:542012. View Article : Google Scholar : PubMed/NCBI | |
|
Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, et al: Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 18:4973–4985. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, et al: Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst. 99:949–961. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Ju W, Renouard J, Aden J, Belinsky SA and Lin Y: 17-allyl-amino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res. 66:1089–1095. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, Wang J, Proia DA, Tailor R, Komaki R, et al: Hsp90 inhibitor ganetespib sensitizes non-small cell lung cancer to radiation but has variable effects with chemoradiation. Clin Cancer Res. 22:5876–5886. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Segawa T, Fujii Y, Tanaka A, Bando S, Okayasu R, Ohnishi K and Kubota N: Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med. 33:559–564. 2014. View Article : Google Scholar | |
|
Camphausen K and Tofilon PJ: Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin Cancer Res. 13:4326–4330. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J and Varticovski L: HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther. 7:1985–1992. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Laszlo A, Thotala D and Hallahan DE: Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. Cancer J. 19:238–246. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Schilling D, Bayer C, Li W, Molls M, Vaupel P and Multhoff G: Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1α. PLoS One. 7:e311102012. View Article : Google Scholar | |
|
Lee JH, Choi KJ, Seo WD, Jang SY, Kim M, Lee BW, Kim JY, Kang S, Park KH, Lee YS, et al: Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90. Int J Mol Med. 27:441–446. 2011.PubMed/NCBI | |
|
Kim WY, Oh SH, Woo JK, Hong WK and Lee HY: Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res. 69:1624–1632. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pépin DPK, Nicolas E, et al: Anti-Müllerian hormone signaling regulates epithelial plasticity and chemoresistance in lung cancer. Cell Rep. 16:657–671. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, et al: Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. 30:2201–2209. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai MS, Weng SH, Chen HJ, Chiu YF, Huang YC, Tseng SC, Kuo YH and Lin YW: Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide. Mol Cancer Ther. 11:561–571. 2012. View Article : Google Scholar | |
|
Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, Furukawa M, Soh J, Asano H, Tsukuda K, et al: Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors. Oncol Rep. 33:1499–1504. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N and Solit DB: Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res. 68:589–596. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SC, Min HY, Choi H, Bae SY, Park KH, Hyun SY, Lee HJ, Moon J, Park SH, Kim JY, et al: Deguelin analogue SH-1242 inhibits Hsp90 activity and exerts potent anticancer efficacy with limited neurotoxicity. Cancer Res. 76:686–699. 2016. View Article : Google Scholar | |
|
Yang YC, Cheng TY, Huang SM, Su CY, Yang PW, Lee JM, Chen CK, Hsiao M, Hua KT and Kuo ML: Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating Hsp90-EGFR association. Oncogene. 35:3387–3398. 2016. View Article : Google Scholar | |
|
Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, et al: Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res. 20:1204–1211. 2014. View Article : Google Scholar : | |
|
Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K and Yano S: Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 5:4920–4928. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, et al: ALK and crizotinib: After the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res. 3:250–261. 2014. | |
|
Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, et al: A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 26:1741–1748. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, et al: A multi-center phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 19:3068–3077. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, et al: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 28:4953–4960. 2010. View Article : Google Scholar : PubMed/NCBI |
